Simulation research supports commitment to advance engineering
of Tumor Treating Fields delivery systems
In total, 60 abstracts on Tumor Treating Fields, including two
oral presentations, will be presented
The volume of Tumor Treating Fields presentations marks a record
number of abstracts for Novocure
Novocure (NASDAQ: NVCR) announced today 10 presentations on
simulation studies aiming to optimize treatment delivery of Tumor
Treating Fields at the 22nd Annual Meeting of the Society for
Neuro-Oncology (SNO), November 16 through November 19, in San
Francisco. These 10 presentations add to the six clinical and 13
preclinical presentations on Tumor Treating Fields at SNO this
year. A total of 60 abstracts on Tumor Treating Fields, including
two oral presentations, will be presented. The volume of Tumor
Treating Fields presentations marks a record number of abstracts
for Novocure and demonstrates what we believe to be a growing
interest in Novocure’s cancer treatment among researchers and
clinicians throughout the world.
The 10 presentations include data on a new array layout that
could allow delivery of TTFields to infra-tentorial brain tumors,
and data showing correlation between TTFields intensity within and
surrounding patients’ tumors and their clinical outcomes.
“Our therapy bridges physics and biology, and presents us with
the opportunity to make clinical advancements and to advance the
engineering of our Tumor Treating Fields delivery systems,” said
Dr. Eilon Kirson, Novocure’s Chief Science Officer and Head of
Research and Development. “Research of the physical application of
Tumor Treating Fields helps us to further understand our cancer
treatment and continue improving our delivery methods.”
Poster presentations
(EXTH-76) Optimizing transducer array configuration for treating
tumors in the infratentorial and supratentorial brain using
Tumor Treating Fields (TTFields). S. Levi. 7:30 – 9:30 p.m. PST
Friday, November 17. (Location: Golden Gate ballroom, B2 level)
(NIMG-66) A method for rapidly creating head models of
Glioblastoma patients for studying the delivery of TTFields to the
brain. N. Urman. 7:30 – 9:30 p.m. PST Friday, November 17.
(Location: Golden Gate ballroom, B2 level)
(EXTH-33) To achieve greater efficacy in tumor-treatment fields:
modeling based on the intracellular mechanisms. K. Carlson. 7:30 –
9:30 p.m. PST Friday, November 17. (Location: Golden Gate ballroom,
B2 level)
(NIMG-18) Creating accurate computational head models of
patients using dataset combining MRI and CT images. A. Naveh. 7:30
– 9:30 p.m. PST Friday, November 17. (Location: Golden Gate
ballroom, B2 level)
(EXTH-22) A new design for transducer arrays for the delivery of
Tumor Treating Fields. Z. Bomzon. 7:30 – 9:30 p.m. PST Friday,
November 17. (Location: Golden Gate ballroom, B2 level)
(EXTH-04) Guiding principles for predicting the distribution of
tumor treating fields in a human brain: A computer modeling study
investigating the impact of tumor position, conductivity
distribution and tissue homogeneity. A.R. Korshoej. 7:30 – 9:30
p.m. PST Friday, November 17. (Location: Golden Gate ballroom, B2
level)
(RTHP-04) Dosimetric impacts from a tumor treating fields
(TTFields) device for glioblastoma multiforme (GBM) patients
undergoing simultaneous radiation therapy. T. Li. 5 – 7 p.m. PST
Saturday, November 18. (Location: Golden Gate ballroom, B2
level)
(RTHP-20) Radiation therapy targeting accuracy when combined
with alternating electric field therapy. J. Grimm. 5 – 7 p.m. PST
Saturday, November 18. (Location: Golden Gate ballroom, B2
level)
(RTHP-06) End-To-End Workflow for Finite Element Analysis of
Tumor Treating Fields in Glioblastomas. J. Timmons. 5 – 7 p.m. PST
Saturday, November 18. (Location: Golden Gate ballroom, B2
level)
(ACTR-91) Numerical simulations of TTFields distribution in
patient models reveals a connection between field intensity and
patient outcome. N. Urman. 5 – 7 p.m. PST Saturday, November 18.
(Location: Golden Gate ballroom, B2 level)
About Novocure
Novocure is an oncology company developing a profoundly
different cancer treatment utilizing a proprietary therapy called
TTFields, the use of electric fields tuned to specific frequencies
to disrupt solid tumor cancer cell division. Novocure’s
commercialized product, Optune, is approved for the treatment of
adult patients with glioblastoma. Novocure has ongoing or completed
clinical trials investigating TTFields in brain metastases,
non-small cell lung cancer, pancreatic cancer, ovarian cancer and
mesothelioma.
Headquartered in Jersey, Novocure has U.S. operations in
Portsmouth, New Hampshire, Malvern, Pennsylvania and New York City.
Additionally, the company has offices in Germany, Switzerland,
Japan and Israel. For additional information about the company,
please visit www.novocure.com or follow us at
www.twitter.com/novocure.
Forward-Looking Statements
In addition to historical facts or statements of current
condition, this press release may contain forward-looking
statements. Forward-looking statements provide Novocure’s current
expectations or forecasts of future events. These may include
statements regarding anticipated scientific progress on its
research programs, development of potential products,
interpretation of clinical results, prospects for regulatory
approval, manufacturing development and capabilities, market
prospects for its products, and other statements regarding matters
that are not historical facts. You may identify some of these
forward-looking statements by the use of words in the statements
such as “anticipate,” “estimate,” “expect,” “project,” “intend,”
“plan,” “believe” or other words and terms of similar meaning.
Novocure’s performance and financial results could differ
materially from those reflected in these forward-looking statements
due to general financial, economic, regulatory and political
conditions as well as more specific risks and uncertainties facing
Novocure such as those set forth in its Annual Report on Form 10-K
filed on February 23, 2017, with the U.S. Securities and Exchange
Commission. Given these risks and uncertainties, any or all of
these forward-looking statements may prove to be incorrect.
Therefore, you should not rely on any such factors or
forward-looking statements. Furthermore, Novocure does not intend
to update publicly any forward-looking statement, except as
required by law. Any forward-looking statements herein speak only
as of the date hereof. The Private Securities Litigation Reform Act
of 1995 permits this discussion.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171109005258/en/
NovocureAshley Cordova, 212-767-7558acordova@novocure.com
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From Aug 2024 to Sep 2024
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From Sep 2023 to Sep 2024